Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson’s Disease and Multiple System Atrophy

Overview

Patients with Parkinson's Disease or Multiple System Atrophy (MSA), and symptoms of orthostatic hypotension, are eligible for the study. Each patient will have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and Unified Parkinson Disease Rating Scale (UPDRS) will be performed after each intervention.

Full Title of Study: “Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson’s Disease and Multiple System Atrophy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Double

Detailed Description

Enrolled patients, ages 40-95, must have Parkinson's or MSA, diagnosed by a neurologist, and symptoms of orthostatic hypotension. Each patient will fill out two validated questionnaires to determine if they are candidates for the study. Baseline patient details, such as their medications and UPDRS, will be recorded. Medications must be held stable during the period of the study. Each patient will then have three weeks of conservative therapy, three weeks of therapy with fludrocortisone, and three weeks of therapy with domperidone. Autonomic testing, a symptom questionnaire, bedside blood pressure testing, and UPDRS will be performed after each intervention.

Interventions

  • Drug: Fludrocortisone
  • Drug: Domperidone
  • Behavioral: Conservative Measures for Orthostatic Hypotension

Clinical Trial Outcome Measures

Primary Measures

  • Efficacy of conservative treatment, domperidone, and fludrocortisone for patient’s subjective symptoms of orthostatic hypotension, and on objective autonomic testing

Participating in This Clinical Trial

Inclusion Criteria

  • Patients residing in Queensland Australia – Age 40-95 – Parkinson's Disease or MSA diagnosed by a neurologist – Symptoms of orthostatic hypotension, as defined by 2 validated questionnaires Exclusion Criteria:

  • Patients with acute cardiomyopathy or cardiac condition – Patients unable to give consent – Patients not stable on their Parkinsonian medications – Patients with another cause for autonomic neuropathy

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 95 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Royal Brisbane and Women’s Hospital
  • Overall Official(s)
    • Kerrie Schoffer, MBBS, Principal Investigator, Movement Disorders Fellow

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.